跳至主要内容
临床试验/NCT03606473
NCT03606473已完成早期 1 期

Exploration of Mechanisms of Effects of Prenatal Cocaine Exposure in Young Adults

Gale Richardson1 个研究点 分布在 1 个国家目标入组 13 人开始时间: 2018年1月24日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
状态
已完成
发起方
入组人数
13
试验地点
1
主要终点
Percent change in Binding potential (BPnd)

研究概览

简要总结

The goal of this study is to use [C-11]NPA and amphetamine (oral, 0.5 mg/kg) to measure striatal dopamine transmission in prenatal cocaine exposed subjects (PCE) and comparison subjects (COMP)

详细描述

Prenatal cocaine exposure (PCE) has consistently been associated with behavioral deficits through childhood, adolescence, and young adulthood in our ongoing study (PRO15080516 - Effects of Prenatal Cocaine Use: 25-Year Follow-Up). Further, 21-year-olds with PCE in our study were twice as likely to have been arrested as non-exposed offspring, were more likely to be diagnosed with Conduct Disorder, had higher disinhibition scores, were significantly more likely to use alcohol and marijuana earlier, and to have earlier sexual intercourse. The effects of PCE on the developing nervous system may cause changes in brain function that underlie these behavioral outcomes.

This study seeks to examine dopamine (DA) transmission in vivo, using positron emission tomography (PET) with [C-11]NPA, in striatal regions of interest in subjects who have a history of exposure to prenatal cocaine (PCE). We hypothesize that PCE is associated with increases in dopamine in the striatum relative to COMP. This may explain the impulsivity and high risk behaviors in PCE subjects

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
25 Years 至 30 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Prenatal cocaine exposed subjects (PCE): Offspring exposed to prenatal cocaine (concurrent exposure to prenatal alcohol and tobacco are not exclusionary) as determined by detailed interviewing during pregnancy
  • Comparison group (COMP): Offspring NOT exposed to prenatal cocaine (exposure to prenatal alcohol and tobacco are not exclusionary) as determined by detailed interviewing during pregnancy.
  • Exclusion criteria for both PCE and COMP groups:
  • No current mania or psychosis based on current mental status exam and SCID-IV modules A (pages A18-A37) and B (pages B1-B8);
  • No current cocaine, heroin, opioid, methadone, benzodiazepine, methamphetamine use (negative urine drug screen at both day of screening and the day of PET scan);
  • No current use of cannabis (a negative urine drug screen on day of PET scan; Note: a positive cannabis urine on the day of screening will not be exclusionary because cannabis tends to be used for recreation; and it takes a long time for it turn negative because it is released from fat cells in body long after subject has quit; and it has been shown to not impact amphetamine-induced dopamine release in prior studies);
  • Not currently taking prescription or over the counter medications that can alter monoamine transmission in the brain or interact with the d-amphetamine challenge or alter amphetamine concentrations (major CYP2D6 inhibitors such as fluoxetine, thioridazine, terbinafine etc., as well as pseudo-ephedrine, atomoxetine, SSRIs, etc.);
  • No use of acidifying (fruit juice; beverages; ascorbic acid) and alkalinizing agents (such as sodium bicarbonate) that alter amphetamine concentrations at least 12 hrs before PET scan day;
  • No current or past severe medical or neurological illnesses such as seizure disorders, head injury with prolonged loss of consciousness, hypertension, prior MI, CAD etc., (determined by physician investigator's elicited medical history, physical exam, review of labs, and EKG results);
  • Not currently pregnant (serum pregnancy test at screening) or breastfeeding;
  • No history of radioactivity exposure via prior nuclear medicine studies or occupational exposure in past 12 months;
  • No metallic objects in the body that are contraindicated for MRI;
  • SBP > 135, DBP > 85, and/or HR ≤ 50 or ≥ 100 (documented before the PET scans; Note: it is not unusual to have to repeat screening vital signs in subjects' because some subjects tend to have white coat syndrome and present with elevated vitals at screening, which later normalizes);
  • No first-degree relative with an MI or stroke or TIA prior to 50 years of age;
  • No first-degree relative with psychosis or mania.

排除标准

  • 未提供

研究组 & 干预措施

Prenatal cocaine exposed subjects

Experimental

[C-11]NPA PET at baseline and post d-amphetamine

干预措施: [C-11]NPA (Radiation)

Prenatal cocaine exposed subjects

Experimental

[C-11]NPA PET at baseline and post d-amphetamine

干预措施: d-amphetamine (Drug)

Comparison subjects

Experimental

[C-11]NPA PET at baseline and post d-amphetamine

干预措施: d-amphetamine (Drug)

Comparison subjects

Experimental

[C-11]NPA PET at baseline and post d-amphetamine

干预措施: [C-11]NPA (Radiation)

结局指标

主要结局

Percent change in Binding potential (BPnd)

时间窗: Baseline BPnd (time 0) and Post-amphetamine BPnd (time 3 hours

DELTA BPND

次要结局

未报告次要终点

研究者

发起方
Gale Richardson
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Gale Richardson

Associate Professor

University of Pittsburgh

研究点 (1)

Loading locations...

相似试验